全文获取类型
收费全文 | 21317篇 |
免费 | 2708篇 |
国内免费 | 517篇 |
专业分类
耳鼻咽喉 | 302篇 |
儿科学 | 611篇 |
妇产科学 | 709篇 |
基础医学 | 1523篇 |
口腔科学 | 698篇 |
临床医学 | 2249篇 |
内科学 | 2863篇 |
皮肤病学 | 206篇 |
神经病学 | 1925篇 |
特种医学 | 509篇 |
外国民族医学 | 11篇 |
外科学 | 3542篇 |
综合类 | 2563篇 |
预防医学 | 1733篇 |
眼科学 | 323篇 |
药学 | 854篇 |
43篇 | |
中国医学 | 513篇 |
肿瘤学 | 3365篇 |
出版年
2024年 | 19篇 |
2023年 | 498篇 |
2022年 | 577篇 |
2021年 | 1079篇 |
2020年 | 1236篇 |
2019年 | 1130篇 |
2018年 | 987篇 |
2017年 | 1062篇 |
2016年 | 1036篇 |
2015年 | 956篇 |
2014年 | 1581篇 |
2013年 | 1533篇 |
2012年 | 1326篇 |
2011年 | 1284篇 |
2010年 | 1045篇 |
2009年 | 986篇 |
2008年 | 971篇 |
2007年 | 974篇 |
2006年 | 851篇 |
2005年 | 754篇 |
2004年 | 585篇 |
2003年 | 600篇 |
2002年 | 496篇 |
2001年 | 442篇 |
2000年 | 296篇 |
1999年 | 291篇 |
1998年 | 250篇 |
1997年 | 216篇 |
1996年 | 190篇 |
1995年 | 192篇 |
1994年 | 142篇 |
1993年 | 141篇 |
1992年 | 112篇 |
1991年 | 91篇 |
1990年 | 80篇 |
1989年 | 79篇 |
1988年 | 67篇 |
1987年 | 37篇 |
1986年 | 45篇 |
1985年 | 61篇 |
1984年 | 38篇 |
1983年 | 32篇 |
1982年 | 30篇 |
1981年 | 30篇 |
1980年 | 21篇 |
1979年 | 18篇 |
1977年 | 11篇 |
1976年 | 12篇 |
1969年 | 8篇 |
1968年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 515 毫秒
1.
随着医疗救治水平的不断提高,早产儿的存活率明显增加,但早产常易伴发脑性瘫痪、运动和认知障碍等一系列神经发育问题,给家庭、社会带来沉重负担。生命早期大脑发育迅速,可塑性强,是进行早期运动干预的良好时机。本文就早产儿早期神经运动干预进行综述,旨在为临床医护人员对早产儿进行适宜有效的运动干预提供参考。 相似文献
2.
[摘要] 目的 评估直接抗病毒药物(direct antivirus agent, DAA)治疗肝移植术后HCV感染复发的有效性和安全性。方法?回顾性分析首都医科大学附属北京佑安医院2011年2月—2018年12月收治的14例肝移植术后HCV感染复发患者的DAA治疗临床数据,比较患者基线与治疗结束后肝肾功能、血常规、凝血功能、病毒学水平以及无创纤维化评分天冬氨酸转氨酶血小板比率指数(aspartate aminotransferase-platelet ratio index, APRI)的差异。利用电子病历系统和电话随访收集患者治疗期间不良反应发生情况。结果?所有患者均在治疗结束时达到病毒学清除,12周、24周持续病毒学应答率均为100%,DAA治疗后随访17~44个月,期间均未见病毒学复发。与基线水平相比,治疗终点时ALT、AST、TBIL、γ-谷氨酰转移酶以及无创纤维化评分APRI显著下降,WBC、HGB、PLT、CRE、肾小球滤过率和血糖等指标均未见显著变化。DAA治疗期间共3例患者发生不良反应,均为轻度,可自然缓解。结论?肝移植术后HCV感染复发的DAA治疗是安全有效的。 相似文献
3.
《Value in health》2022,25(1):69-76
ObjectivesThere is limited knowledge about the cost patterns of patients who receive a diagnosis of de novo and recurrent advanced cancers in the United States.MethodsData on patients who received a diagnosis of de novo stage IV or recurrent breast, colorectal, or lung cancer between 2000 and 2012 from 3 integrated health systems were used to estimate average annual costs for total, ambulatory, inpatient, medication, and other services during (1) 12 months preceding de novo or recurrent diagnosis (preindex) and (2) diagnosis month through 11 months after (postindex), from the payer perspective. Generalized linear regression models estimated costs adjusting for patient and clinical factors.ResultsPatients who developed a recurrence <1 year after their initial cancer diagnosis had significantly higher total costs in the preindex period than those with recurrence ≥1 year after initial diagnosis and those with de novo stage IV disease across all cancers (all P < .05). Patients with de novo stage IV breast and colorectal cancer had significantly higher total costs in the postindex period than patients with cancer recurrent in <1 year and ≥1 year (all P < .05), respectively. Patients in de novo stage IV and those with recurrence in ≥1 year experienced significantly higher postindex costs than the preindex period (all P < .001).ConclusionsOur findings reveal distinct cost patterns between patients with de novo stage IV, recurrent <1-year, and recurrent ≥1-year cancer, suggesting unique care trajectories that may influence resource use and planning. Future cost studies among patients with advanced cancer should account for de novo versus recurrent diagnoses and timing of recurrence to obtain estimates that accurately reflect these care pattern complexities. 相似文献
4.
5.
《The Journal for Nurse Practitioners》2022,18(2):140-146
Early detection and improved treatments for breast cancer are increasing survival rates, thereby growing the number of survivors to almost 4 million in the United States. Continuing care after treatment is frequently provided in primary care. Evidence-based care includes a history review, physical examination, and imaging for recurrence and new cancers, along with health maintenance and health promotion. Additionally, survivors often experience long-term side effects from their disease and/or treatment, affecting health and quality of life. This article provides a synopsis of breast cancer treatment-related side effects and current evidence-based guidelines to assist the primary care provider caring for survivors. 相似文献
6.
7.
《European journal of surgical oncology》2022,48(1):82-88
BackgroundWhereas the usefulness of radiofrequency (RF) energy as haemostatic method in liver surgery has become well established in the last decades, its intentional application on resection margins with the aim of reducing local recurrence is still debatable. Our goal was to compare the impact of an additional application of RF energy on the top of the resection surface, namely additional margin coagulation (AMC), on local recurrence (LR) when subjected to a subcentimeter margin.MethodsWe retrospectively analyzed 185 patients out of a whole cohort of 283 patients who underwent radical hepatic resection with subcentimetric margin. After propensity score adjustment, patients were classified into two balanced groups according to whether RF was applied or not.ResultsNo significant differences were observed within groups in baseline characteristics after PSM adjustment. The LR rate was significantly higher in the Control than AMC Group: 12 patients (14.5%) vs. 4 patients (4.8%) (p = 0.039). The estimated 1, 3, and 5-year LR-free survival rates of patients in the Control and AMC Group were: 93.5%, 86.0%, 81.0% and 98.8%, 97.2%, 91.9%, respectively (p = 0.049). Univariate Cox analyses indicated that the use of the RF applicator was significantly associated with lower LR (HR = 0.29, 95% confidence interval 0.093–0.906, p = 0.033). The Control Group showed smaller coagulation widths than the AMC group (p < 0.001).ConclusionsAn additional application of RF on the top of the resection surface is associated with less local hepatic recurrence than the use of conventional techniques. 相似文献
8.
9.
10.